Nanobodies

Camelid nanobodies show promise for brain disorders in mice, review says

07 novembre 2025 Riportato dall'IA Immagine generata dall'IA Verificato

A Cell Press review published on November 5, 2025, highlights tiny camelid-derived antibodies known as nanobodies as potential tools for treating conditions such as Alzheimer’s disease and schizophrenia. The authors say these proteins can reach brain targets in mice more readily than conventional antibodies and outline key steps before human testing.